A new competitor for EpiPen has been approved by the U.S. Food and Drug Administration.
The emergency injection device to treat life-threatening allergic reactions is called Symjepi and is made by Adamis Pharmaceuticals Corp., the Associated Press reported.
Latest Allergies News
Symjepi is meant to be a "low-cost alternative" to EpiPen and similar products, and Adamis wants to sell it for less than generic EpiPens, according to company spokesman Mark Flather.
EpiPens have soared in price in recent years, prompting concern from doctors and patients alike.
An exact price has not been set for Symjepi, which will be sold in pairs like EpiPen, the AP reported.
Copyright © 2017 HealthDay. All rights reserved.
Subscribe to MedicineNet's Allergy and Asthma Newsletter